Langmu Medical Completes Tens of Millions RMB Pre-A Financing to Advance Original Ophthalmic Innovations

VCBeat (WeChat: vcbeat) has learned at the earliest opportunity that recently,Langmu MedicalAnnounced the completion ofQiming Venture Partners Leads Investment，Oriza Holdings and existing shareholder Danlu Capital participated in the follow-on investmenttens of millions of yuan in Pre-A round financing, which will be primarily used for new product R&D and the clinical trials and registration of innovative medical devices.

Langmu Medical is a technology-driven startup focused on innovative ophthalmic medical devices, with its current primary focus on minimally invasive treatment devices for glaucoma. Leveraging the founding team’s background in integrating medicine and engineering, the Langmu Medical team not only possesses a profound understanding of clinical needs but also boasts strong R&D capabilities in engineering. Furthermore,The team’s unique international perspective and experience have also made Langmu Medical one of the few companies in China that truly possess proprietary technologies in the field of minimally invasive glaucoma surgery (MIGS).。

The ophthalmology market has experienced rapid growth in recent years, with its scale reaching nearly RMB 200 billion, making it one of the most sought-after industries today. China currently has at least 400 million patients suffering from eye diseases. As the population ages and modern lifestyles alter visual habits, the burden of eye diseases in China is expected to continue increasing, indicating substantial room for future growth in the ophthalmology market. Data shows that both the ophthalmic pharmaceuticals and ophthalmic medical device segments in China are still dominated by foreign companies. In certain high-end niche segments of ophthalmology, the market share of imported suppliers exceeds 95%.

Taking the market for minimally invasive glaucoma treatments as an example. Glaucoma is the leading cause of irreversible blindness worldwide, with over 88 million patients globally, 60% of whom are in Asia. In China, the number of patients has exceeded 22 million. Due to the many limitations of traditional glaucoma surgeries, Micro-Invasive Glaucoma Surgery (MIGS), which has developed rapidly in recent years, has become the mainstream trend in industry development. However, all currently marketed MIGS products are developed by European and American companies for open-angle glaucoma and are not suitable for angle-closure glaucoma, which is highly prevalent in Asia. Currently, there are no products from domestic enterprises available on the market.

Langmu Medical Team, combining original innovative surgical techniques for glaucoma treatment,Independently developed AqueFish, an original Chinese innovative stent product for glaucoma treatment™, not only can it significantly improve the success rate of glaucoma surgery, but it will also be one of the few stent products internationally that are applicable to both angle-closure glaucoma and open-angle glaucoma, holding significant importance for glaucoma treatment. At the same time,Langmu Medical is also continuously deepening its expertise in other ophthalmic fields, having established multiple innovative ophthalmic product pipelines.will be successively approved for market launch between 2024 and 2025. In addition, the company’s founding team consists entirely of high-caliber overseas returnees from internationally renowned universities, bringing a global perspective to its development. It was revealed thatLangmu Medical has recently signed multi-million-dollar cooperation agreements with a U.S. ophthalmic innovation technology company and a globally leading German medical device company to jointly expand into domestic and international ophthalmology markets.。

Regarding Langmu Medical's current round of financing,Zhang Ao, Executive Director at Qiming Venture Partners“The statement reads: ‘Langmu Medical is one of the few domestic companies specializing in minimally invasive glaucoma surgical (MIGS) devices with proprietary technologies. Qiming Venture Partners holds a highly favorable view of the company’s innovative technologies, R&D capabilities, and growth potential in the ophthalmology sector. With increasing emphasis on intellectual property protection by enterprises both domestically and internationally in recent years, Langmu Medical is well-positioned to leverage its original technologies to drive the development of China’s glaucoma diagnosis and treatment market, secure a foothold in the international arena, and deliver more and better treatment options for glaucoma patients worldwide.’”

Song Yongyin, Investment Director at Oriza Holdings“Glaucoma is an irreversible ophthalmic disease with a significant risk of blindness, and Oriza Holdings remains committed to this field. Currently, patients in China have only two options: medication and traditional surgery. We anticipate that the emergence and diversification of MIGS (Minimally Invasive Glaucoma Surgery) products will provide patients with more beneficial treatment choices. Langmu Medical’s proprietary product pipeline, the team’s profound understanding of surgical procedures, and their global R&D perspective are the foundations of Oriza Holdings’ confidence. We look forward to collaborating with Langmu Medical to benefit more patients with eye diseases.”

Liang Qiao, Vice President of Investment at Redhill Capital“Stated: ‘There remain many unmet clinical needs in the field of ophthalmology, and glaucoma treatment is receiving increasing attention. Based on the integration of medicine and engineering, and addressing critical clinical pain points, Langmu Medical has proposed an innovative treatment solution for glaucoma. As an angel-round investor, we have witnessed Langmu Medical’s growth from a single founder into a robust enterprise, during which the team has demonstrated exceptional execution capabilities. Danlu remains optimistic about the company and its team, is committed to growing alongside the company, and firmly believes that Chinese innovations will inevitably make their mark on the global stage.’”

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages ten U.S. dollar funds and six RMB funds, with total assets under management exceeding US$6.2 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as TMT and Healthcare.

To date, Qiming Venture Partners has invested in over 430 high-growth innovative enterprises, among which more than 170 have achieved exits through listings on exchanges such as the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange, the Taipei Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, as well as through mergers and acquisitions. Over 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

Oriza Yuan Dian is a specialized early-stage equity investment platform under Oriza Holdings, operating on a market-oriented basis. It focuses primarily on investment opportunities in start-ups and early-growth enterprises within the technology and healthcare sectors. With 13 funds under its management totaling approximately RMB 5 billion, its portfolio includes both venture capital (VC) funds and angel funds targeted at specific regions. Adhering to an investment style that emphasizes early-stage ventures, prioritizes technological innovation, and honors commitments, Oriza Yuan Dian is dedicated to empowering entrepreneurial companies with growth momentum and growing alongside founders.

Danlu Capital is a venture capital firm dedicated to the healthcare and medical industry. Co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner at Fenxiang Investment Management, the firm has consistently deepened its focus on the early-stage healthcare sector. It has systematically built a portfolio spanning innovative medical technologies—including high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health—as well as innovative drugs and novel medical services.

Redhill Capital is committed to rewarding investors with outstanding performance. We aim to leverage the power of capital to accelerate the R&D and commercialization of modern medical and pharmaceutical technologies, thereby improving public health and wellness, and striving to become a trusted, enduring, and premier healthcare fund management firm.